Background

• Eccrine carcinoma, also known as malignant eccrine poroma, is a infrequent and aggressive form of skin cancer originating from the sweat glands. The sweat glands, particularly the eccrine glands, regulate body temperature by secreting sweat onto the skin’s surface. Eccrine carcinoma arises when there is an uncontrolled proliferation of malignant cells within these sweat glands. This type of cancer typically develops in areas of the body with a high concentration of sweat glands, such as the palms, soles of the feet, armpits, and face. While the exact cause of eccrine carcinoma remains unclear, it is thought to be linked to prolonged sun exposure, ionizing radiation exposure, and specific genetic mutations. 
• Eccrine carcinoma usually presents as a painless, slow-growing nodule or ulcer on the skin, which can be mistaken for benign skin conditions initially. However, diagnosing and treating it early is crucial, as it can potentially metastasize to other organs and tissues, leading to a poorer prognosis. Treatment options for eccrine carcinoma often involve surgical excision to remove the tumor and surrounding tissues, coupled with other therapies like radiation or chemotherapy, based on the stage and extent of the cancer. Due to its rarity and the challenges in diagnosing it accurately, eccrine carcinoma requires a multidisciplinary approach involving dermatologists, oncologists, and pathologists to ensure timely and effective management. 

Epidemiology

Eccrine Carcinoma is a rare type of skin cancer that originates from the sweat glands.  

• Incidence Rate: Eccrine Carcinoma is a rare skin cancer with a low incidence rate, accounting for less than 0.001% of all tumors. 
• Age Group Affected: Eccrine Carcinoma typically affects individuals between 60 and 70 years old. 
• Gender Predilection: Limited epidemiological data suggest a higher incidence of Eccrine Carcinoma in non-Hispanic White men. Gender distribution seems to be comparable for eccrine carcinoma. However, there are instances where primary cutaneous adenoid cystic eccrine carcinoma and malignant chondroid syringoma are more prevalent in females than in males. 
• Anatomical Distribution: Eccrine Carcinoma commonly occurs on the head, neck, lower extremities, and trunk. 

Anatomy

Pathophysiology

The pathophysiology of Eccrine Carcinoma has yet to be fully understood due to its rarity and complexity. Eccrine carcinoma is believed to arise from the malignant transformation of eccrine sweat gland cells, specifically the secretory portion of the eccrine glands.  

• Genetic Mutations: Like many cancers, genetic mutations play a crucial role in the pathogenesis of eccrine carcinoma. Specific genetic alterations can lead to the uncontrolled growth and proliferation of cells in the eccrine glands, giving rise to cancer. Mutations in tumor suppressor genes (e.g., TP53) and oncogenes (e.g., HRAS) have been associated with eccrine carcinoma development. 
• Prolonged Sun Exposure: Ultraviolet (UV) radiation from the sun can damage the DNA of the skin cells, including those in the sweat glands. Chronic and excessive sun exposure is a significant risk factor for skin cancers, including eccrine carcinoma. 
• Ionizing Radiation: Exposure to ionizing radiation, like in radiation therapy for other cancers or occupational radiation exposure, has been linked to an enhanced risk of developing eccrine carcinoma. 
• Immunocompromised States: Individuals with weakened immune systems, such as organ transplant recipients or those with certain immunodeficiency disorders, may be more susceptible to developing eccrine carcinoma. 
• Precursor Lesions: Certain benign skin conditions, like eccrine poroma, have been identified as potential precursor lesions that can progress to eccrine carcinoma. These lesions may undergo malignant transformation over time, leading to cancer formation. 

Etiology

The etiology of Eccrine Carcinoma, also known as malignant eccrine poroma, still needs to be discovered because of its rarity and the limited number of cases available for study.  

• Genetic Factors: Genetic mutations are believed to play a significant role in the etiology of eccrine carcinoma. Mutations in specific genes, such as TP53, a tumor suppressor gene, and HRAS, an oncogene, have been found in some cases of eccrine carcinoma. These mutations can lead to the uncontrolled cell growth and the formation of tumors. 
• Prolonged Sun Exposure: Ultraviolet (UV) radiation from the sun can damage the DNA in skin cells, including those in the sweat glands. Chronic and excessive sun exposure is a well-known risk factor for various skin cancers, including eccrine carcinoma. 
• Radiation Exposure: People exposed to ionizing radiation through medical treatments like radiation therapy or occupational exposure may have an increased risk of developing eccrine carcinoma. 
• Age and Gender: Eccrine carcinoma is more commonly seen in older individuals, typically over 50. It appears to occur more frequently in men than women. 
• Immunocompromised States: Individuals with weakened immune systems, such as organ transplant recipients or those with certain immunodeficiency disorders, may have an elevated risk of developing eccrine carcinoma. 
• Precursor Lesions: Certain benign skin conditions, such as eccrine poroma, have been suggested to serve as potential precursor lesions for eccrine carcinoma. These benign lesions can undergo malignant transformation over time, giving rise to cancer. 
• Hereditary Syndromes: In some rare cases, eccrine carcinoma may be associated with hereditary syndromes, such as Brooke-Spiegler syndrome and Schopf-Schulz-Passarge syndrome. These syndromes involve mutations in specific genes that increase the risk of various skin tumors, including eccrine carcinoma. 

Genetics

Prognostic Factors

The prognostic factors of Eccrine Carcinoma, like many cancers, can vary depending on several prognostic factors that influence the disease’s behavior and treatment outcomes.  

• Tumor Stage: At the time of diagnosis, the tumor stage is one of the most significant prognostic factors. The tumor stage generally refers to the size of the tumor, the extent of its local invasion, and whether it has spread to nearby lymph nodes or distant organs (metastasis). Generally, earlier-stage tumors have a better prognosis than more advanced ones. 
• Tumor Size and Depth: Larger tumors and those with deeper invasion into surrounding tissues tend to have a poorer prognosis. Tumor depth is often measured in millimeters and is an important factor in assessing the risk of metastasis. 
• Lymph Node Involvement: Cancer cells in regional lymph nodes indicate a higher risk of spreading to other parts of the body, negatively impacting prognosis. Lymph node involvement is often assessed by performing a biopsy or through imaging studies. 
• Metastasis: The spread of Eccrine Carcinoma to distant organs (metastasis) significantly worsens the prognosis. Advanced stages of the disease with metastatic involvement are associated with poorer outcomes. 
• Histological Grade: The histological grade refers to the degree of differentiation of the cancer cells when examined under a microscope. Well-differentiated tumors tend to have a better prognosis than poorly differentiated ones. 
• Patient’s Age and General Health: Older age and overall health status can influence how well a patient tolerates treatments and responds to therapies, affecting the prognosis. 
• Immune Status: Immunocompromised individuals may have a less favorable prognosis, such as those with certain medical conditions or taking immunosuppressive medications. 
• Surgical Margins: The completeness of tumor removal during surgery is crucial. Wide surgical margins are associated with better outcomes, reducing the risk of local recurrence. 
• Response to Treatment: How well the tumor responds to initial treatments, such as surgery, radiation therapy, or chemotherapy, can impact the long-term prognosis. 
• Genetic Factors: Specific genetic mutations in the tumor may influence its aggressiveness and response to therapies. 

Clinical History

• Age Group:  
• Eccrine Carcinoma can occur in individuals of any age, but it is most commonly diagnosed in older adults, typically over 50. However, it can also affect younger individuals, albeit less frequently.  

Physical Examination

During a physical examination of a suspected Eccrine Carcinoma, a healthcare professional, typically a dermatologist or oncologist, will carefully inspect the skin and assess the characteristics of the skin lesion.  

• History Taking: The healthcare provider will begin by generally taking a detailed medical history, including any symptoms the patient is experiencing, the duration of the skin lesion, and any relevant risk factors, such as sun exposure, previous radiation therapy, or immunosuppression. 
• Visual Inspection: The doctor will visually examine the skin lesion. Eccrine Carcinomas typically appear as flesh-colored or pink nodules, papules, or ulcers on the skin, often on areas with a high concentration of sweat glands, such as the palms, soles, armpits, or face. The appearance of the lesion, its size, shape, and color will be noted. 
• Palpation: The healthcare provider may gently palpate the skin lesion using their fingers to assess the tumor’s texture, consistency, and depth. Palpation can help determine if the lesion is raised, firm, or ulcerated. 
• Lymph Node Examination: Since Eccrine Carcinoma can spread to nearby lymph nodes, the doctor will also check for any enlarged or palpable lymph nodes nearby. Enlarged lymph nodes may indicate possible metastasis. 
• Dermoscopy: Sometimes, the doctor may use a dermatoscope—a handheld magnifying instrument with a light—to examine the skin lesion more closely. Dermoscopy allows for a more detailed evaluation of the lesion’s surface and structure, aiding in the diagnosis. 
• Biopsy: A skin biopsy is often performed to confirm the diagnosis of Eccrine Carcinoma definitively. During this procedure, a tissue sample from the skin lesion is removed and sent to a laboratory for microscopic examination by a pathologist. The biopsy can help distinguish Eccrine Carcinoma from other skin conditions and determine its characteristics, including its grade and stage.

Age group

Associated comorbidity

Associated activity

• No specific associated comorbidities or activities universally predispose individuals to Eccrine Carcinoma. However, certain risk factors, such as prolonged sun exposure, ionizing radiation exposure, and immunosuppression, may play a role in developing this skin cancer. People with conditions that weaken the immune system, such as organ transplant recipients, may have a higher risk of developing Eccrine Carcinoma. 

Acuity of presentation

Eccrine Carcinoma typically presents as a slow-growing lesion on the skin. The tumor may start as a painless, small, flesh-colored, pink nodule or a papule. Over time, it can enlarge and become more noticeable. The lesion may have a shiny or smooth surface and can resemble other benign skin conditions initially, leading to potential delays in diagnosis. 

• Location: Eccrine Carcinoma often arises in areas of the body with a high concentration of sweat glands, such as the palms, soles of the feet, armpits, and face. However, it can occur on any part of the body. 
• Ulceration and Bleeding: As the tumor grows, it may ulcerate, forming an open sore prone to bleeding. This can be a more advanced sign of Eccrine Carcinoma. 
• Mimicry of Benign Conditions: Eccrine Carcinoma can sometimes mimic other benign skin conditions, like eccrine poroma, making its diagnosis challenging. A skin biopsy is often necessary for definitive diagnosis and to differentiate it from benign lesions. 
• Aggressiveness: Eccrine Carcinoma is considered an aggressive form of skin cancer. In some cases, it can invade surrounding tissues and metastasize to nearby lymph nodes or distant organs, leading to a poorer prognosis. 
• Pain: While Eccrine Carcinoma is often painless in the early stages, it can become painful as the tumor grows, invades more profound tissues, or becomes ulcerated. 

Differential Diagnoses

Diagnosing Eccrine Carcinoma can be challenging due to its rarity and the similarity of its clinical presentation with other skin lesions. Several skin conditions and tumors may be considered in the differential diagnosis of Eccrine Carcinoma.  

• Eccrine Poroma: It is a benign tumor that arises from the eccrine sweat gland ducts. It can resemble Eccrine Carcinoma, making it an important consideration in the differential diagnosis. A biopsy is required to differentiate between the two conditions. 
• Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer and often appears as a pink or pearly nodule with a rolled border. In some cases, BCC can also have a similar appearance to Eccrine Carcinoma, mainly when it arises in areas with sweat glands. 
• Squamous Cell Carcinoma (SCC): SCC is another common type of skin cancer that can present as a firm, pink or red nodule or an ulcerated lesion. It may be mistaken for Eccrine Carcinoma, particularly in areas with sweat glands. 
• Melanoma: It is a type of skin cancer originating from melanocytes, which produce skin pigment (melanin). In some cases, nodular or amelanotic melanoma can present as a flesh-colored or pink nodule, which may be confused with Eccrine Carcinoma. 
• Dermatofibrosarcoma Protuberans (DFSP): DFSP is a rare type of soft tissue sarcoma that can present as a slow-growing nodule on the skin. It may appear similar to Eccrine Carcinoma, and a biopsy is needed to distinguish between them. 
• Metastatic Carcinoma: In some cases, metastatic carcinoma, which is cancer that has spread to the skin from other organs, may present as a skin nodule or ulceration. Careful evaluation of the patient’s medical history and additional testing can help differentiate metastatic carcinoma from primary Eccrine Carcinoma. 
• Adnexal Tumors: Other adnexal tumors, such as sebaceous carcinoma or cylindroma, can sometimes overlap with Eccrine Carcinoma and may need to be considered in the differential diagnosis. 

Laboratory Studies

Imaging Studies

Procedures

Histologic Findings

Staging

Treatment Paradigm

• The treatment paradigm of Eccrine Carcinoma involves a multidisciplinary approach and depends on the tumor’s stage, size, location, and the patient’s overall health. The primary treatment for localized Eccrine Carcinoma is surgical excision with the wide margins to ensure complete tumor removal and diminish the risk of local recurrence.
• Additional therapies like radiation therapy or chemotherapy may be recommended for more advanced cases or those with lymph node involvement or metastasis. In some instances, targeted therapies or immunotherapies may be considered based on specific genetic mutations or biomarkers found in the tumor. Regular follow-up and surveillance are essential to monitor for potential recurrence or metastasis. The management should be individualized, considering the patient’s age, comorbidities, and preferences, to achieve optimal disease control and preserve the quality of life. 

by Stage

by Modality

Chemotherapy

Radiation Therapy

Surgical Interventions

Hormone Therapy

Immunotherapy

Hyperthermia

Photodynamic Therapy

Stem Cell Transplant

Targeted Therapy

Palliative Care

use-of-the-non-pharmacological-therapy-for-modifying-the-environment

Radiation Oncologist 

• The modification of the environment in the context of Eccrine Carcinoma primarily revolves around prevention and reducing exposure to potential risk factors that may contribute to the development or progression of cancer. Since Eccrine Carcinoma is associated with factors like sun exposure and ionizing radiation, modifying the environment to minimize these influences can be beneficial.  
• Sun Protection: Reducing sun exposure and practicing sun-protective measures can helps to lower the risk of skin cancers, including Eccrine Carcinoma. Individuals should seek shade during peak sun hours, wear protective clothing, and regularly apply a broad-spectrum sunscreen with at least SPF 30/higher. 

• Avoiding Tanning Beds: Tanning beds emit harmful UV radiation and should be avoided to reduce the risk of skin cancer. 
• Protective Clothing: People working in environments with potential exposure to ionizing radiation should use appropriate protective clothing and gear to minimize radiation exposure. 
• Regular Skin Examinations: Regular self-skin examinations and professional skin checks by a dermatologist can helps in the early detection and prompt treatment of any suspicious skin lesions, including Eccrine Carcinoma. 
• Immunization: For individuals with weakened immune systems or those at risk of immunosuppression, following recommended vaccination schedules can help prevent infections and support overall immune health. 
• Lifestyle: Adopting a healthy lifestyle, together with a balanced diet, regular exercise activities, and avoiding smoking and alcohol consumption, can contribute to overall well-being, potentially reducing the risk of cancer development. 

Use of Surgical Excision for managing Eccrine Carcinoma

The surgical procedure aims to remove the entire tumor while minimizing the chances of recurrence. Depending on the size and location of the carcinoma, the surgery may be performed in different ways: 

• Simple Excision: A simple excision might be performed in cases where the tumor is relatively small and superficial.  
• Mohs Surgery: Eccrine carcinomas can be challenging to treat due to their aggressive nature and tendency to recur. In some cases, Mohs micrographic surgery may be used. This technique involves removing thin layers of tissue one at a time and also examining them under a microscope to make sure that all cancer cells are typically removed while preserving as much healthy tissue as possible. 
• Wide Local Excision: A wide local excision may be necessary for larger tumors or those with deeper invasion. In this procedure, a larger area of surrounding healthy tissue is removed to ensure complete tumor removal. 

Use of radiation therapy for managing Eccrine Carcinoma

Radiation therapy is one of the therapy options that may be considered for eccrine carcinoma in certain cases.  

• Adjuvant Therapy: After surgical excision, radiation therapy may be recommended if there is a concern that some cancer cells may remain in the area or if there is a high risk of the tumor recurring. Radiation can help destroy any leftover cancer cells and diminish the chances of the tumor coming back. 
• Primary Treatment: In some cases, especially if surgery is not an option or if the tumor is large and difficult to remove surgically, radiation therapy might be used as the primary treatment. 
• External Beam Radiation: The common type of radiation therapy used for eccrine carcinoma is external beam radiation.  
• Side Effects: Radiation therapy might cause side effects, which may vary depending on the location of the tumor and the dose of radiation used. Common side effects like include skin irritation, redness, and fatigue. These side effects are usually temporary and will subside after the completion of treatment. 
• Follow-Up Care: After radiation therapy, regular follow-up visits will be scheduled to monitor the individual progress, assess treatment response, and manage any potential side effects. 

Use of chemotherapy for managing Eccrine Carcinoma

• chemotherapy is generally not considered a first-line treatment for eccrine carcinoma. This is because eccrine carcinoma is not very responsive to traditional chemotherapy agents. 
• In certain cases where eccrine carcinoma has metastasized (spread to other parts of the body) or if it is a high-grade or aggressive form, systemic treatments like chemotherapy may be considered as part of the treatment plan. Chemotherapy for eccrine carcinoma is typically reserved for advanced cases where surgery and radiation alone are not sufficient to control the cancer. 
• The specific chemotherapy drugs used will depend on the individual case and the judgment of the medical oncologist. There is no standardized or established chemotherapy regimen for eccrine carcinoma due to its rarity and the lack of large-scale clinical trials specifically focusing on this cancer type. Therefore, treatment decisions are often made based on the best available evidence and the experience of the medical team. 

use-of-intervention-with-a-procedure-in-treating-eccrine-carcinoma

The primary treatment intervention for Eccrine Carcinoma involves surgical procedures to remove the tumor and surrounding tissues. The choice of procedure depends on the tumor’s size, location, extent of invasion, and the patient’s overall health.  

• Wide Local Excision: This is the standard surgical approach for early-stage Eccrine Carcinoma. The surgeon removes the tumor and also a margin of the healthy tissue around it to ensure complete removal. The amount of tissue removed depends on the tumor size and the estimated depth of invasion. 
• Mohs Micrographic Surgery: Mohs surgery is a specialized technique used for treating certain types of skin cancer, including Eccrine Carcinoma, located in areas where tissue preservation is critical, such as the face. During the procedure, the surgeon removes thin layers of tissue and examines them under a microscope immediately, layer by layer, until no cancer cells are detected. 
• Lymph Node Dissection: If there is evidence of lymph node involvement, a surgical procedure called lymph node dissection may be performed. In this procedure, the nearby lymph nodes are removed and also examined to determine the extent of spread and inform further treatment decisions. 
• Electrodessication and Curettage (ED&C): This procedure involves scraping the tumor with a sharp spoon-like instrument and then utilizing an electric current to destroy any remaining cancer cells. 
• Radiation Therapy: In certain cases, radiation therapy may be used as a primary treatment or in combination with surgery, especially for larger tumors, those with high-risk features, or when complete surgical removal is challenging. 
• Chemotherapy: Chemotherapy, which involves using drugs to kill cancer cells, may be considered for advanced cases of Eccrine Carcinoma or when the cancer has spread to distant organs (metastatic disease). 
• Targeted Therapies: Some cases of Eccrine Carcinoma may exhibit specific genetic mutations that can be targeted with certain medications. These targeted therapies aim to block the abnormal signaling pathways within cancer cells. 

use-of-phases-in-managing-eccrine-carcinoma

The treatment phase of management for Eccrine Carcinoma involves various stages, starting from diagnosis and proceeding through the chosen treatment modalities.  

• Diagnosis: The management process begins with a thorough clinical evaluation, which includes a physical examination and a review of the patient’s medical history. Suspicious skin lesions are biopsied, and the tissue samples are typically sent to a pathology laboratory for histological examination to substantiate the diagnosis of Eccrine Carcinoma. 

• Staging and Assessment: After the diagnosis is confirmed, additional tests and imaging studies may be conducted to determine the stage and extent of the cancer. This staging process helps understand the tumor’s size, depth of invasion, lymph node involvement, and whether it has metastasized to other body parts. 
• Treatment Planning: Based on the stage and characteristics of Eccrine Carcinoma, a multidisciplinary team of healthcare professionals, including dermatologists, oncologists, and surgeons, collaborates to develop a personalized treatment plan. The plan considers the patient’s age, overall health, and preferences. 
• Surgical Intervention: In early-stage Eccrine Carcinoma, the primary treatment is often surgical excision, aiming to remove the tumor with wide margins to ensure complete removal and reduce the risk of recurrence. Procedures like Mohs surgery or lymph node dissection may be performed as needed. 
• Adjuvant Therapies: In some instances, additional therapies may be recommended to complement surgery and improve treatment outcomes. Adjuvant therapies may include radiation therapy to target any remaining cancer cells or chemotherapy to target potential micro-metastases. 
• Monitoring and Surveillance: Following treatment, regular follow-up appointments are scheduled to monitor the patient’s progress, check for any signs of recurrence, and manage potential treatment-related side effects. 
• Palliative Care: In cases of advanced or metastatic Eccrine Carcinoma where curative treatment is not possible, palliative care is employed to enhance the patient’s quality of life, manage symptoms, and provide supportive care. 
• Targeted Therapies and Clinical Trials: For individuals with specific genetic mutations or those with recurrent or metastatic disease, targeted therapies and participation in clinical trials may be considered to explore new treatment options and novel therapeutic approaches. 

Medication

Future Trends

Media Gallary

References

• Eccrine Carcinoma – StatPearls – NCBI Bookshelf (nih.gov) 
• Frontiers | Case report: Case report and literature review: Treatment of sweat gland carcinoma (frontiersin.org) 
• Eccrine Porocarcinoma: A Rare Cutaneous Tumor (dermatologytimes.com) 
• Epidemiology and Survival of Eccrine Porocarcinoma by Sex in the United States: A Surveillance, Epidemiology, and End Results Database Analysis – PubMed (nih.gov)